Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting
I'm PortAI, I can summarize articles.
Curis Inc. will present new clinical and preclinical data on emavusertib at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. The data includes studies on primary and secondary CNS lymphomas, covering genetic mutation profiles, CNS pharmacokinetics, safety and efficacy of drug combinations, and potential efficacy signals. The results will be presented by researchers from leading institutions and have not yet been disclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments